Updates from Syncona and our portfolio companies
ANV419 is a powerful and selective interleukin-2 (IL-2) agonist targeting cancer
Anaveon, an immuno-oncology company, today announced that it will present a poster at the Society for Immunotherapy of Cancer’s (SITC) 35th Virtual Annual Meeting being held from Monday, November 9, 2020 to Saturday, November 14, 2020.
Syncona Ltd ("Syncona") announces a CHF 28 million (£21.4 million) commitment to Anaveon, a new immuno-oncology company, in a CHF 35 million (£26.8 million) Series A financing alongside the Novartis Venture Fund. Syncona will have a 47.0 per cent stake in the business.